Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2022 · 10-K
Revenue$330.20M$330.20M−54.9% vs Q4 2021 Net Income-$67.00M-$67.00MN/M vs Q4 2021 EPS Diluted-$1.34-$1.34N/M vs Q4 2021 Gross Profitderived$100,100,000−76.7% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Income-$55,300,000N/M Operating Cash Flowderived$92,800,000−71.7% Free Cash Flowderived$69,200,000−75.5% Margins · derivedGross margin30.3%−28.4 pt vs Q4 2021
Operating margin-16.7%−55.9 pt vs Q4 2021
Net margin-20.3%−46.6 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 1, 2023 · 60 d after period end